Background

With the explosion of COVID-19 globally, it was unclear if people with Parkinson’s disease (PD) were at increased risk for severe manifestations or negative outcomes.

Objectives

To report on people with PD who had suspected or confirmed COVID-19 to understand how COVID-19 manifested in PD patients.

Methods

We surveyed PD patients who reported COVID-19 to their Movement Disorders specialists at Columbia University Irving Medical Center and respondents from an online survey administered by the Parkinson’s Foundation that assessed COVID-19 symptoms, general clinical outcomes and changes in motor and non-motor PD symptoms.

Results

Forty-six participants with PD and COVID-19 were enrolled. Similar to the general population, the manifestations of COVID-19 among people with PD were heterogeneous ranging from asymptomatic carriers (1/46) to death (6/46). The most commonly reported COVID-19 symptoms were fever/chills, fatigue, cough, weight loss, and muscle pain. Worsening and new onset of motor and non-motor PD symptoms during COVID-19 illness were also reported, including dyskinesia, rigidity, balance disturbances, anxiety, depression, and insomnia.

Conclusion

We did not find sufficient evidence that PD is an independent risk factor for severe COVID-19 and death. Larger studies with controls are required to understand this further. Longitudinal follow-up of these participants will allow for observation of possible long-term effects of COVID-19 in PD patients.

中文翻译：

---

帕金森病患者的 COVID-19 表现：美国队列

背景

随着全球 COVID-19 的爆发，目前尚不清楚帕金森病 (PD) 患者出现严重表现或负面结果的风险是否增加。

目标

报告疑似或确诊 COVID-19 的 PD 患者，以了解 COVID-19 在 PD 患者中的表现。

方法

我们调查了向哥伦比亚大学欧文医学中心的运动障碍专家报告 COVID-19 的 PD 患者，以及帕金森基金会管理的在线调查的受访者，该调查评估了 COVID-19 症状、一般临床结果以及运动和非运动 PD 的变化症状。

结果

招募了 46 名患有 PD 和 COVID-19 的参与者。与普通人群相似，PD 患者中 COVID-19 的表现是异质的，从无症状携带者 (1/46) 到死亡 (6/46)。最常报告的 COVID-19 症状是发烧/发冷、疲劳、咳嗽、体重减轻和肌肉疼痛。还报告了 COVID-19 疾病期间运动和非运动 PD 症状的恶化和新发作，包括运动障碍、僵硬、平衡障碍、焦虑、抑郁和失眠。

结论

我们没有发现足够的证据表明 PD 是严重 COVID-19 和死亡的独立危险因素。需要更大规模的对照研究来进一步理解这一点。这些参与者的纵向随访将允许观察 COVID-19 对 PD 患者可能的长期影响。